Gilead gets ball rolling on JAKs game in Japan

Gilead is gear­ing up for a full JAK1 launch.

Four days af­ter sub­mit­ting an NDA for their new JAK1 in­hibitor for rheuma­toid arthri­tis, fil­go­tinib, the phar­ma gi­ant has hand­ed dis­tri­b­u­tion and co-pro­mo­tion rights in Japan to Ei­sai, should it be ap­proved on the is­lands. Gilead has al­ready sub­mit­ted the drug for reg­u­la­to­ry ap­proval there.

Dol­lar terms of the deal were not an­nounced, though they are like­ly size­able giv­en the drug’s block­buster pro­jec­tions. Glob­al peak sales es­ti­mates have ranged as high as $6 bil­lion and tend to come in at around $3 bil­lion. Eval­u­atePhar­ma has of­fered a more con­ser­v­a­tive $1.1 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER